最新的帖子

十二月 23, 2020

Container Closure Integrity Evaluation for Cell and Gene Therapies

With the growth of gene and cell therapies, there is an increased need to characterize container closure systems (CCS) at the low temperatures experienced during their lifecycles: ultra-low (-80°C) for genes and cryogenic (-180°C) for cells. West’s Integrated Solutions platform includes the state-of-the-art container closure integrity (CCI) capabilities needed for these therapies.
Olga Laskina

Olga Laskina, PhD.

Sr. Technical Account Specialist, TCS NA

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • 以前的博客
    SmartDose Platform

    六月 27, 2019

    Industry Trends in Biologic Formulations

    Victoria Morgan

    Victoria Morgan

    Director, Segment Marketing, Global Biologics

    SmartDose In-Use

    五月 07, 2019

    The Impact Poor Formulations Have on Drug Development Programs

    Victoria Morgan

    Victoria Morgan

    Director, Segment Marketing, Global Biologics

    SmartDose Platform

    四月 26, 2019

    Overcoming Challenges Associated with Biologic Drug Formulation and Development

    Victoria Morgan

    Victoria Morgan

    Director, Segment Marketing, Global Biologics